Delivers like nothing else.
BOLD CLINICAL TRIALS
Two randomised control trials.1,2
Exceptional outcomes at 2-Years7. No matter the lesion complexity. No matter the patient.
In the RANGER II SFA RCT, Ranger demonstrated 84% K-M primary patency at 2-Years.7
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.